Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cedric Hermans

Showing results (201-210 of 222) with videos related to

Pageof 23
Sort By:
Biomedicine Hub|May 14, 2021
Propelling Healthcare with Advanced Therapy Medicinal Products: A Policy DiscussionDenis Horgan, Andres Metspalu, Marie-Christine Ouillade, et al.
Medicine|October 9, 2015
A French National Survey on Clotting Disorders in MastocytosisAna B Carvalhosa, Achille Aouba, Gandhi Damaj, et al.
The Lancet. Haematology|April 21, 2019
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 studySteven W Pipe, Midori Shima, Michaela Lehle, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 27, 2025
Operationalising a Haemophilia Gene Editing Lexicon for Practical UseWilliam McKeown, Cedric Hermans, Carmen Unzu, et al.
Thrombosis and Haemostasis|September 10, 2021
New Inhibitors in the Ageing Population: A Retrospective, Observational, Cohort Study of New Inhibitors in Older People with HemophiliaJan Astermark, Cihan Ay, Manuela Carvalho, et al.
Research and Practice in Thrombosis and Haemostasis|February 27, 2026
Etranacogene dezaparvovec in people with hemophilia B with preexisting adeno-associated virus 5 neutralizing antibodies: 4-year subgroup results from the HOPE-B trialRobert Klamroth, Paul E Monahan, Paul Van der Valk, et al.
The Lancet. Haematology|January 30, 2023
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 studyClaude Négrier, Johnny Mahlangu, Michaela Lehle, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 22, 2024
A novel gene editing lexicon strategy for the haemophilia community: Research plan for development and preliminary resultsCedric Hermans, Leonard A Valentino, Courtney D Thornburg, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 22, 2022
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A - A modified Delphi consensus by the ADVANCE Working GroupRobert Klamroth, Cihan Ay, Philippe De Moerloose, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 21, 2023
Prevalence of COVID-19 related hospitalizations and mortality in adults aged ≥40 years with haemophilia: A survey from EuropeCedric Hermans, Jan Astermark, Manuela Carvalho, et al.
Pageof 23

Showing results (201-210 of 222) with videos related to

Sort By:
Pageof 23
Biomedicine Hub|May 14, 2021
Propelling Healthcare with Advanced Therapy Medicinal Products: A Policy DiscussionDenis Horgan, Andres Metspalu, Marie-Christine Ouillade, et al.
Medicine|October 9, 2015
A French National Survey on Clotting Disorders in MastocytosisAna B Carvalhosa, Achille Aouba, Gandhi Damaj, et al.
The Lancet. Haematology|April 21, 2019
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 studySteven W Pipe, Midori Shima, Michaela Lehle, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 27, 2025
Operationalising a Haemophilia Gene Editing Lexicon for Practical UseWilliam McKeown, Cedric Hermans, Carmen Unzu, et al.
Thrombosis and Haemostasis|September 10, 2021
New Inhibitors in the Ageing Population: A Retrospective, Observational, Cohort Study of New Inhibitors in Older People with HemophiliaJan Astermark, Cihan Ay, Manuela Carvalho, et al.
Research and Practice in Thrombosis and Haemostasis|February 27, 2026
Etranacogene dezaparvovec in people with hemophilia B with preexisting adeno-associated virus 5 neutralizing antibodies: 4-year subgroup results from the HOPE-B trialRobert Klamroth, Paul E Monahan, Paul Van der Valk, et al.
The Lancet. Haematology|January 30, 2023
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 studyClaude Négrier, Johnny Mahlangu, Michaela Lehle, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 22, 2024
A novel gene editing lexicon strategy for the haemophilia community: Research plan for development and preliminary resultsCedric Hermans, Leonard A Valentino, Courtney D Thornburg, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 22, 2022
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A - A modified Delphi consensus by the ADVANCE Working GroupRobert Klamroth, Cihan Ay, Philippe De Moerloose, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 21, 2023
Prevalence of COVID-19 related hospitalizations and mortality in adults aged ≥40 years with haemophilia: A survey from EuropeCedric Hermans, Jan Astermark, Manuela Carvalho, et al.
Pageof 23